Evidence map›Paper›PMID 34239412›Full record

ArticleFrontiers in neuroscience2021

Small, Seeding-Competent Huntingtin Fibrils Are Prominent Aggregate Species in Brains of zQ175 Huntington's Disease Knock-in Mice.

Franziska Schindler, Nicole Praedel, Nancy Neuendorf, Severine Kunz, Sigrid Schnoegl, Michael A Mason, Bridget A Taxy, Gillian P Bates, Ali Khoshnan, Josef Priller and 4 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in neuroscience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Detection of antibodies against the huntingtin protein in human plasma.Cellular and molecular life sciences : CMLS · 2023
    Article
  4. Article
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 4 countries.

Franziska SchindlerNeuroproteomics, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.
Nicole PraedelNeuroproteomics, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.
Nancy NeuendorfNeuroproteomics, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.
Severine KunzNeuroproteomics, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.
Sigrid SchnoeglNeuroproteomics, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.
Michael A MasonHuntington's Disease Centre, Department of Neurodegenerative Disease, UK Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.
Bridget A TaxyHuntington's Disease Centre, Department of Neurodegenerative Disease, UK Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.
Gillian P BatesHuntington's Disease Centre, Department of Neurodegenerative Disease, UK Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.
Ali KhoshnanDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, United States.
Josef PrillerDepartment of Psychiatry and Psychotherapy, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany.
Jan GrimmNeurimmune AG, Schlieren, Switzerland.
Marcel MaierNeurimmune AG, Schlieren, Switzerland.
Annett BoeddrichNeuroproteomics, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.
Erich E WankerNeuroproteomics, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.
Max Delbrück Center · DELight Chain Bioscience (Switzerland) · CHUniversity College London · GBCalifornia Institute of Technology · USNational Hospital for Neurology and Neurosurgery · GBTechnical University of Munich · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The deposition of mutant huntingtin (mHTT) protein aggregates in neurons of patients is a pathological hallmark of Huntington's disease (HD). Previous investigations in cell-free and cell-based disease models showed mHTT exon-1 (mHTTex1) fragments with pathogenic polyglutamine (polyQ) tracts (>40 glutamines) to self-assemble into highly stable, β-sheet-rich protein aggregates with a fibrillar morphology. HD knock-in mouse models have not been extensively studied with regard to mHTT aggregation. They endogenously produce full-length mHTT with a pathogenic polyQ tract as well as mHTTex1 fragments. Here, we demonstrate that seeding-competent, fibrillar mHTT aggregates can be readily detected in brains of zQ175 knock-in HD mice. To do this, we applied a highly sensitive FRET-based protein amplification assay that is capable of detecting seeding-competent mHTT aggregate species down to the femtomolar range. Furthermore, we show that fibrillar structures with an average length of ∼200 nm can be enriched with aggregate-specific mouse and human antibodies from zQ175 mouse brain extracts through immunoprecipitations, confirming that such structures are formed

Indexed as

aggregatesbrainFRASE assayHuntington’s diseasemHTTprotein misfoldingseedingzQ175

Identifiers

PMID34239412
PMCPMC8257939
OpenAlexW3174420790

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.